Journal ArticleDOI
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
TLDR
The use of an anthracycline-containing regimen was not associated with an improved outcome in PTCL-NOS or angioimmunoblastic type, but was associated with a better outcome in anaplastic large-cell lymphoma, ALK positive.Abstract:
Purpose Peripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTCL) are rare and heterogeneous forms of non-Hodgkin’s lymphoma (NHL) that, in general, are associated with a poor clinical outcome. Patients and Methods A cohort of 1,314 cases of PTCL and NKTCL was organized from 22 centers worldwide, consisting of patients with previously untreated PTCL or NKTCL who were diagnosed between 1990 and 2002. Tissue biopsies, immunophenotypic markers, molecular genetic studies, and clinical information from consecutive patients at each site were reviewed by panels of four expert hematopathologists and classified according to the WHO classification. Results A diagnosis of PTCL or NKTCL was confirmed in 1,153 (87.8%) of the cases. The most common subtypes were PTCL not otherwise specified (NOS; 25.9%), angioimmunoblastic type (18.5%), NKTCL (10.4%), and adult T-cell leukemia/lymphoma (ATLL; 9.6%). Misclassification occurred in 10.4% of the cases including Hodgkin’s lymphoma (3%), B-cell lymphoma (1.4%), unclassifiable lymphoma (2.8%), or a diagnosis other than lymphoma (2.3%). We found marked variation in the frequency of the various subtypes by geographic region. The use of an anthracycline-containing regimen was not associated with an improved outcome in PTCL-NOS or angioimmunoblastic type, but was associated with an improved outcome in anaplastic large-cell lymphoma, ALK positive. Conclusion The WHO classification is useful for defining subtypes of PTCL and NKTCL. However, expert hematopathology review is important for accurate diagnosis. The clinical outcome for patients with most of these lymphoma subtypes is poor with standard therapies, and novel agents and new modalities are needed to improve survival. J Clin Oncol 26:4124-4130. © 2008 by American Society of Clinical Oncologyread more
Citations
More filters
Journal ArticleDOI
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.
TL;DR: The criteria and significance of early or precursor lesions and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly are addressed, and the issue of borderline categories having overlapping features with large B-cell lymphomas is reviewed.
Journal ArticleDOI
Non-Hodgkin lymphoma.
TL;DR: Since this topic was last reviewed in The Lancet in 2012, advances in understanding the biology and genetics of non-Hodgkin lymphoma and the availability of new diagnostic methods and therapies have improved the ability to manage patients with this disorder.
Journal ArticleDOI
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project
Wing Yan Au,Dennis D. Weisenburger,Tanin Intragumtornchai,Shigeo Nakamura,Won Seog Kim,Ivy Sng,Julie M. Vose,James O. Armitage,Raymond Liang +8 more
TL;DR: It is concluded that the clinical features and treatment response of extranasal NK/T-cell lymphoma are different from of those of nasal lymphoma, however, the underlying features responsible for these differences remain to be defined.
Journal ArticleDOI
Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study
Takashi Ishida,Tatsuro Joh,Naokuni Uike,Kazuhito Yamamoto,Atae Utsunomiya,Shinichiro Yoshida,Yoshio Saburi,Toshihiro Miyamoto,Shigeki Takemoto,Hitoshi Suzushima,Kunihiro Tsukasaki,Kisato Nosaka,Hiroshi Fujiwara,Kenji Ishitsuka,Hiroshi Inagaki,Michinori Ogura,Shiro Akinaga,Masao Tomonaga,Kensei Tobinai,Ryuzo Ueda +19 more
TL;DR: KW-0761 demonstrated clinically meaningful antitumor activity in patients with relapsed ATL, with an acceptable toxicity profile, and further investigation of KW-761 for treatment of ATL and other T-cell neoplasms is warranted.
Journal ArticleDOI
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier,Barbara Pro,H. Miles Prince,Francine M. Foss,Lubomir Sokol,Matthew Greenwood,Dolores Caballero,Peter Borchmann,Franck Morschhauser,Martin Wilhelm,Lauren Pinter-Brown,Swaminathan Padmanabhan,Andrei R. Shustov,Jean Nichols,Susan Carroll,John Balser,Barbara Balser,Steven M. Horwitz +17 more
TL;DR: Single-agent romidepsin induced complete and durable responses with manageable toxicity in patients with relapsed or refractory peripheral T-cell lymphoma across all major PTCL subtypes, regardless of the number or type of prior therapies.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
A revised European-American classification of lymphoid neoplasms : a proposal from the international lymphoma study group
Nancy L. Harris,Elaine S. Jaffe,Harald Stein,Peter M. Banks,John K.C. Chan,Michael L. Cleary,Georges Delsol,C. De Wolf Peeters,Brunangelo Falini,K C Gatter +9 more
Journal ArticleDOI
E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues
Journal Article
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more
TL;DR: The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.
Related Papers (5)
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier,Barbara Pro,H. Miles Prince,Francine M. Foss,Lubomir Sokol,Matthew Greenwood,Dolores Caballero,Peter Borchmann,Franck Morschhauser,Martin Wilhelm,Lauren Pinter-Brown,Swaminathan Padmanabhan,Andrei R. Shustov,Jean Nichols,Susan Carroll,John Balser,Barbara Balser,Steven M. Horwitz +17 more